Australia markets close in 2 hours 5 minutes

Cogstate Limited (CGS.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
1.1100-0.0050 (-0.45%)
As of 01:37PM AEST. Market open.

Cogstate Limited

367 Collins Street
Level 32
Melbourne, VIC 3000
Australia
61 3 9664 1300
https://www.cogstate.com

Sector(s)Healthcare
IndustryHealth Information Services
Full-time employees158

Key executives

NameTitlePayExercisedYear born
Mr. Bradley John O'Connor B.Bus, C.A., CACEO, MD & Executive Director887.04kN/AN/A
Prof. Paul Maruff BBSc (Hons), Ph.D.Founder & Chief Innovation OfficerN/AN/AN/A
Mr. Darren WatsonChief Financial Officer539.01kN/AN/A
Mr. Benjamin BloomfieldChief Technology Officer454.5kN/AN/A
Dr. Chris Edgar Ph.D.Chief Science Officer509.24kN/AN/A
Mr. Kenneth BillardChief Commercial Officer631.32kN/AN/A
Ms. Rachel ColiteExecutive VP of Clinical Trials440.17kN/AN/A
Ms. Kristi GeddesGeneral Counsel, Joint Company Secretary & DirectorN/AN/AN/A
Mr. David James Franks BEc, C.A., F Fin, J.P.Joint Company SecretaryN/AN/A1970
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Cogstate Limited, a neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research. Its cognitive services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. The company is also involved in the design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its technology and associated services are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The company also provides Cognigram, a system for regular and standardized testing to assist primary care physicians and/or hospitals in the early detection of cognitive decline. As of June 30, 2023, it had participated in approximately 1,800 academic research studies and 530 industry sponsored clinical trials. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.

Corporate governance

Cogstate Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.